• Karyopharm highlighted Phase 3 SENTRY topline data in JAK inhibitor-naïve myelofibrosis, showing selinexor with ruxolitinib met the co-primary endpoint on spleen volume reduction at week 24.
• SVR35 at week 24 was 49.8% for selinexor with ruxolitinib versus 28% for placebo with ruxolitinib, with an odds ratio of 2.58; p<0.0001.
• The symptom co-primary endpoint missed, with an adjusted mean difference of 0.97 in absolute total symptom score change at week 24; p=0.8246.
• Secondary analyses showed an overall survival signal with a hazard ratio of 0.43; nominal p=0.0222, with 11 deaths in the combination arm versus 12 in the control arm.
• Topline results were also flagged as expected mid-2026 from the Phase 3 XPORT-EC-042 trial of selinexor in TP53 wild-type endometrial cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.